This study assesses the usefulness of new metabolic imaging with deuterated glucose and magnetic resonance spectroscopy (MRS) in patients with glioma. Deuterium (also known as heavy hydrogen)-labeled glucose is a form of non-radioactive sugar. MRS detects the chemical composition of the brain. Information gained in this study may help doctors learn more metabolic information about brain tumors. It is hoped that this information will help researchers learn more about practical ways of evaluating treatment, which may benefit future patients with brain tumors.
Additional locations may be listed on ClinicalTrials.gov for NCT06594315.
Locations matching your search criteria
United States
California
San Francisco
University of California San FranciscoStatus: Active
Contact: Yan Li
Phone: 415-514-2104
PRIMARY OBJECTIVES:
I. To define the most appropriate imaging parameters of MRS for obtaining deuterium-labeled glucose metabolism.
II. To evaluate treatment induced metabolic changes after the administration of deuterated glucose (deuterium [2H]-glucose) in patients in glioma.
OUTLINE: This is an observational study. Participants are assigned to 1 of 3 cohorts.
COHORT I: Healthy volunteers receive 2H-glucose orally (PO) and undergo MRS scan once on study. Healthy volunteers also undergo collection of blood on the day of MRS scan.
COHORT II: Patients with glioma receive 2H-glucose PO and undergo MRS scan once on study. Patients also undergo collection of blood on the day of MRS scan.
COHORT III: Patients with glioma receive 2H-glucose PO and undergo MRS scans 0-14 days before start of treatment and 7-21 days after completion of treatment. Patients also undergo collection of blood on each day of MRS scan.
Trial PhaseNo phase specified
Trial Typediagnostic
Lead OrganizationUniversity of California San Francisco
Principal InvestigatorYan Li